Dashboard
Manage Tickers

INCYINCYTE CORP

Nasdaq incyte.com


$ 53.68 $ 0.24 (0.45 %)    

Tuesday, 16-Apr-2024 14:16:48 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 431.90 $ 0.89 (0.21 %)
DIA $ 378.30 $ -1.11 (-0.29 %)
SPY $ 504.21 $ -0.54 (-0.11 %)
TLT $ 88.35 $ 0.24 (0.27 %)
GLD $ 221.40 $ 0.45 (0.2 %)
$ 53.43
$ 53.44
$ 53.66 x 200
$ 0.00 x 0
$ 53.41 - $ 54.08
$ 50.27 - $ 75.74
1,574,419
na
12.07B
$ 0.53
$ 20.20
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 02-13-2024 12-31-2023 10-K
2 10-31-2023 09-30-2023 10-Q
3 08-01-2023 06-30-2023 10-Q
4 05-02-2023 03-31-2023 10-Q
5 02-07-2023 12-31-2022 10-K
6 11-01-2022 09-30-2022 10-Q
7 08-02-2022 06-30-2022 10-Q
8 05-03-2022 03-31-2022 10-Q
9 02-08-2022 12-31-2021 10-K
10 11-02-2021 09-30-2021 10-Q
11 08-03-2021 06-30-2021 10-Q
12 05-04-2021 03-31-2021 10-Q
13 02-09-2021 12-31-2020 10-K
14 11-05-2020 09-30-2020 10-Q
15 08-04-2020 06-30-2020 10-Q
16 05-05-2020 03-31-2020 10-Q
17 02-13-2020 12-31-2019 10-K
18 10-30-2019 09-30-2019 10-Q
19 07-30-2019 06-30-2019 10-Q
20 04-30-2019 03-31-2019 10-Q
21 02-14-2019 12-31-2018 10-K
22 10-30-2018 09-30-2018 10-Q
23 07-31-2018 06-30-2018 10-Q
24 05-01-2018 03-31-2018 10-Q
25 02-15-2018 12-31-2017 10-K
26 10-31-2017 09-30-2017 10-Q
27 08-01-2017 06-30-2017 10-Q
28 05-04-2017 03-31-2017 10-Q
29 02-14-2017 12-31-2016 10-K
30 11-01-2016 09-30-2016 10-Q
31 08-09-2016 06-30-2016 10-Q
32 05-09-2016 03-31-2016 10-Q
33 02-12-2016 12-31-2015 10-K
34 11-03-2015 09-30-2015 10-Q
35 08-04-2015 06-30-2015 10-Q
36 04-30-2015 03-31-2015 10-Q
37 02-17-2015 12-31-2014 10-K
38 10-30-2014 09-30-2014 10-Q
39 07-31-2014 06-30-2014 10-Q
40 05-01-2014 03-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

china-medical-system-announced-collaboration-and-license-agreement-with-incyte-for-selective-oral-smallmolecule-jak1-inhibitor-povorcitinib
China Medical System Announced Collaborati...
04/01/2024 10:40:18

China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that ...

rbc-capital-reiterates-sector-perform-on-incyte-maintains-65-price-target
RBC Capital Reiterates Sector Perform on I...
03/25/2024 14:26:55

RBC Capital analyst Brian Abrahams reiterates Incyte (NASDAQ:INCY) with a Sector Perform and maintains $65 price target.

b-of-a-securities-maintains-neutral-on-incyte-lowers-price-target-to-67
B of A Securities Maintains Neutral on Inc...
03/13/2024 12:04:54

B of A Securities analyst Tazeen Ahmad maintains Incyte (NASDAQ:INCY) with a Neutral and lowers the price target from $69 to...

stifel-reiterates-hold-on-incyte-maintains-68-price-target
Stifel Reiterates Hold on Incyte, Maintain...
03/12/2024 16:33:51

Stifel analyst Stephen Willey reiterates Incyte (NASDAQ:INCY) with a Hold and maintains $68 price target.

incyte-stock-a-deep-dive-into-analyst-perspectives-8-ratings
Incyte Stock: A Deep Dive Into Analyst Per...
03/12/2024 16:00:56

rbc-capital-reiterates-sector-perform-on-incyte-maintains-65-price-target
RBC Capital Reiterates Sector Perform on I...
03/12/2024 15:15:02

RBC Capital analyst Brian Abrahams reiterates Incyte (NASDAQ:INCY) with a Sector Perform and maintains $65 price target.

sunday-incyte-announced-results-from-a-phase-2-study-of-povorcitinib-incb54707-the-study-met-its-primary-endpoint-with-improvement-in-itch-compared-to-placebo-in-prurigo-nodularis
Sunday, Incyte Announced Results From A Ph...
03/11/2024 09:35:59

sunday-incyte-announced-new-results-from-phase-2-study-of-ruxolitinib-cream-opzelura-in-hidradenitis-suppurativa-the-study-met-its-primary-endpoint-demonstrating-significant-reduction-in-abscess-inflammatory-nodule-count-versus-vehicle-control
Sunday, Incyte Announced New Results From ...
03/11/2024 09:34:21

new-data-from-incytes-dermatology-portfolio-to-be-presented-at-the-2024-american-academy-of-dermatology-annual-meeting
New Data From Incyte's Dermatology Portfol...
03/04/2024 13:24:20

Two late-breaking abstracts have been accepted for oral presentation, including randomized studies evaluating ruxolitinib cream...

incyte-announces-fda-grants-priority-review-for-axatilimab-for-chronic-graft-versus-host-disease
Incyte Announces FDA Grants Priority Revie...
02/27/2024 22:44:02

jefferies-initiates-coverage-on-incyte-with-buy-rating-announces-price-target-of-81
Jefferies Initiates Coverage On Incyte wit...
02/23/2024 10:54:32

Jefferies analyst Kelly Shi initiates coverage on Incyte (NASDAQ:INCY) with a Buy rating and announces Price Target of $81.

jmp-securities-downgrades-incyte-to-market-perform
JMP Securities Downgrades Incyte to Market...
02/14/2024 18:13:02

JMP Securities analyst Reni Benjamin downgrades Incyte (NASDAQ:INCY) from Market Outperform to Market Perform.

rbc-capital-maintains-sector-perform-on-incyte-raises-price-target-to-65
RBC Capital Maintains Sector Perform on In...
02/14/2024 15:24:41

RBC Capital analyst Brian Abrahams maintains Incyte (NASDAQ:INCY) with a Sector Perform and raises the price target from $63...

the-analyst-verdict-incyte-in-the-eyes-of-8-experts
The Analyst Verdict: Incyte In The Eyes Of...
02/14/2024 14:00:21

incyte-says-advancing-high-potential-pipeline-provides-opportunity-for-over-10-new-launches-by-2030
Incyte Says Advancing High Potential Pipel...
02/13/2024 12:12:20

incyte-expects-2024-jakafi-net-product-revenues-of-269b-275b
Incyte Expects 2024 Jakafi Net Product Rev...
02/13/2024 12:11:33

Incyte's guidance includes revenues and expenses related to the recently announced acquisition of exclusive global rights t...

incyte-q4-adj-eps-106-misses-116-estimate-sales-101b-beat-100b-estimate
Incyte Q4 Adj EPS $1.06 Misses $1.16 Estim...
02/13/2024 12:05:52

Incyte (NASDAQ:INCY) reported quarterly Adj earnings of $1.06 per share which missed the analyst consensus estimate of $1.16 by...

earnings-scheduled-for-february-13-2024
Earnings Scheduled For February 13, 2024
02/13/2024 10:05:59

Companies Reporting Before The Bell • LCI Indus (NYSE:LCII) is likely to report quarterly earnings at $0.18 per share on reven...

novartis-agrees-to-acquire-german-blood-cancer-drug-developer-morphosys-for-27b
Novartis Agrees To Acquire German Blood Ca...
02/06/2024 13:46:05

Novartis' €2.7 billion public takeover offer for MorphoSys, unlocking a promising oncology pipeline with pelabresib and tul...

Core News & Articles
Incyte Enters Asset Purchase Agreement Wit...
02/05/2024 21:48:42

Incyte gains exclusive global rights for tafasitamab, a humanized Fc-modifiedCD19-targeting immunotherapy marketed in the U.S. ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

04/16/2024 Sunnova Energy International Inc. (NOVA)
04/22/2024 Dick's Sporting Goods, Inc. (DKS)
04/22/2024 Innodata Inc. (INOD)
04/22/2024 Fox Factory Holding Corp. (FOXF)
04/23/2024 Lantronix, Inc. (LTRX)

NEW CASE INVESTIGATION

AnaptysBio Inc (ANAB)